| 2025 | 2024 | 2023 | 2022 | 2018 | 2017 | 2016 | 2015 | 2013 | 2010 | 2009 | 2008 | 2007 | 2006 | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 107,0 M € | +6.5% | 100,4 M € | +16.3% | 86,3 M € | +4.6% | 82,5 M € | +61.6% | 51,1 M € | +17.8% | 43,4 M € | +135.1% | 18,4 M € | -24.3% | 24,4 M € | +367.4% | 5,2 M € | -10.2% | 5,8 M € | -26.3% | 7,9 M € | +161.2% | 3,0 M € | +95.1% | 1,5 M € | -92.1% | 19,5 M € | |
| EBITDA | -1,1 M € | -222.2% | 910,0 k € | -66.7% | 2,7 M € | +25.7% | 2,2 M € | +34.6% | 1,6 M € | +1.0% | 1,6 M € | +260.4% | 444,0 k € | +14.6% | 387,6 k € | +185.8% | 135,6 k € | -27.4% | 186,8 k € | +34.3% | 139,1 k € | +202.5% | -135,8 k € | -104.2% | 3,2 M € | +489.3% | 546,0 k € | |
| Operating profit | -1,5 M € | -268.7% | 910,0 k € | -66.7% | 2,7 M € | +25.8% | 2,2 M € | +51.2% | 1,4 M € | +15.8% | 1,2 M € | +184.3% | 437,0 k € | +14.8% | 380,6 k € | +180.6% | 135,6 k € | -9.5% | 149,9 k € | +12.0% | 133,8 k € | +193.4% | -143,3 k € | -104.5% | 3,2 M € | +491.7% | 540,5 k € | |
| Profit/loss | 32,0 k € | +146.9% | 12,9 k € | -99.0% | 1,3 M € | -18.7% | 1,6 M € | +18.4% | 1,3 M € | -37.2% | 2,1 M € | +693.6% | 268,7 k € | +285.9% | 69,6 k € | +710.8% | 8,6 k € | -99.4% | 1,5 M € | -99.4% | 237,3 M € | +1428760.1% | -16,6 k € | -100.6% | 3,0 M € | -49.2% | 5,9 M € | |
| Equity | 18,5 M € | +0.2% | 18,4 M € | +0.1% | 18,4 M € | +7.5% | 17,1 M € | +39.8% | 12,2 M € | +12.3% | 10,9 M € | +24.3% | 8,8 M € | +3.2% | 8,5 M € | +5.0% | 8,1 M € | -63.3% | 22,0 M € | +7.4% | 20,5 M € | +809.9% | 2,3 M € | -0.7% | 2,3 M € | +161.3% | -3,7 M € | |
| Total assets | 66,5 M € | +38.0% | 48,2 M € | -1.0% | 48,7 M € | +27.9% | 38,1 M € | +52.1% | 25,0 M € | -15.0% | 29,4 M € | +111.8% | 13,9 M € | -12.1% | 15,8 M € | +92.1% | 8,2 M € | -63.3% | 22,4 M € | +5.9% | 21,2 M € | +365.1% | 4,6 M € | +68.0% | 2,7 M € | -85.1% | 18,2 M € | |
| Cash | 107,0 k € | -5.4% | 113,1 k € | -0.6% | 113,8 k € | -0.5% | 114,3 k € | +13.3% | 100,9 k € | -3.0% | 104,0 k € | +0.4% | 103,6 k € | +15.0% | 90,0 k € | +21.2% | 74,3 k € | -94.6% | 1,4 M € | +298.4% | 348,2 k € | +243.3% | 101,4 k € | -88.8% | 907,8 k € | -74.3% | 3,5 M € | |
| Debts | 47,2 M € | +58.4% | 29,8 M € | -1.7% | 30,3 M € | +44.6% | 21,0 M € | +63.8% | 12,8 M € | -31.0% | 18,5 M € | +261.6% | 5,1 M € | -29.8% | 7,3 M € | +5553.7% | 129,1 k € | -67.1% | 392,7 k € | -40.1% | 655,1 k € | -68.8% | 2,1 M € | +1033.8% | 185,5 k € | -99.2% | 21,9 M € | |
| Staff | 1 | 1,3 | 1,3 | 2 | 2,2 | 2,4 | 1 | 1,8 | 2 | 1 | 2,1 | 3 | 3,4 | 4,4 | ||||||||||||||
Public limited company · Machelen (Brab.) · incorporated on 31/08/1995 · 1,0 ETP
Public limited company profitable and well capitalised. Cash position declining (-5.4%).
Solid counterparty for a standard engagement.
OMRIX BIOPHARMACEUTICALS is a Public limited company incorporated in 1995. Its main activity is: Wholesale of pharmaceutical goods. Its registered office is in Machelen (Brab.). It employs on average 1,0 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette